201. Development of a new effective African swine fever virus vaccine candidate by deletion of the H240R and MGF505-7R genes results in protective immunity against the Eurasia strain.
- Author
-
Li J, Song J, Zhou S, Li S, Liu J, Li T, Zhang Z, Zhang X, He X, Chen W, Zheng J, Zhao D, Bu Z, Huang L, and Weng C
- Subjects
- Animals, African Swine Fever immunology, African Swine Fever prevention & control, African Swine Fever virology, Sus scrofa virology, Viral Proteins genetics, Virulence, Virus Replication, African Swine Fever Virus classification, African Swine Fever Virus immunology, African Swine Fever Virus pathogenicity, Vaccines, Attenuated immunology, Viral Vaccines genetics, Viral Vaccines immunology, Gene Deletion, Genes, Viral genetics
- Abstract
Importance: African swine fever (ASF) caused by ASF virus (ASFV) is a highly contagious and acute hemorrhagic viral disease in domestic pigs. Until now, no effective commercial vaccine and antiviral drugs are available for ASF control. Here, we generated a new live-attenuated vaccine candidate (ASFV-ΔH240R-Δ7R) by deleting H240R and MGF505-7R genes from the highly pathogenic ASFV HLJ/18 genome. Piglets immunized with ASFV-ΔH240R-Δ7R were safe without any ASF-related signs and produced specific antibodies against p30. Challenged with a virulent ASFV HLJ/18, the piglets immunized with high-dose group (105 HAD50) exhibited 100% protection without clinical symptoms, showing that low levels of virus replication with no observed pathogenicity by postmortem and histological analysis. Overall, our results provided a new strategy by designing live-attenuated vaccine candidate, resulting in protection against ASFV infection., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF